Mikael Dolsten removes himself from board candidacy at Novo; Bavarian Nordic chairman resigns
Alex Hoffman / endpoints - → In what appears to be another blow to Novo Nordisk, ex-Pfizer CSO Mikael Dolsten has withdrawn his nomination to join the company's board of directors due to ...
AI Summary: Merck has made a blockbuster move by finalizing a $9.2 billion deal to acquire Cidara Therapeutics’ late‐stage anti‐influenza candidate. This acquisition underscores Merck’s commitment to expanding its antiviral portfolio and marks a key strategic investment in advancing flu prevention amid evolving global health threats.
Related Stories
Merck Eyes $30B Deal for Revolution Medicines Acquisition / 5 months
Sanofi’s $2.2B Dynavax Acquisition Boosts Vaccine Portfolio / 6 months
Biogen announces $5.6B acquisition of Apellis Pharma / 3 months
Gilead buys Ouro Medicines for about $1.68–1.7B to bolster autoimmune pipeline / 3 months
Novartis closes Avidity deal; Atrium Therapeutics spinout launches / 4 months
Eli Lilly buys Orna to sprint into in‑vivo CAR‑T therapeutics / 4 months
Novartis pays $100M upfront for macrocyclic peptide platform / 4 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Supply Chain, Health IT, Nutrition, Drug Pricing and look for the RSS link.
StackHealth Time Machine